Publication Name	World Journal of Clinical Cases
Manuscript ID	101196
Country	Netherlands

Received	2024-09-06 21:54
Peer-Review Started	2024-09-06 21:54
To Make the First Decision
Return for Revision	2025-01-16 00:27
Revised	2025-02-09 15:20
Second Decision	2025-02-17 02:45
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-02-17 07:30
Articles in Press	2025-02-17 07:30
Publication Fee Transferred
Edit the Manuscript by Language Editor	2025-02-22 19:53
Typeset the Manuscript	2025-03-03 10:41
Publish the Manuscript Online	2025-03-19 06:12

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Urology & Nephrology
Manuscript Type	Editorial
Article Title	Treatment of immunoglobulin A nephropathy: A current perspective and future prospects
Manuscript Source	Invited Manuscript
All Author List	Yusuf Ziya Şener and Seher Şener
ORCID	Author(s) ORCID Number Yusuf Ziya Şener http://orcid.org/0000-0001-5151-5133 Seher Şener http://orcid.org/0000-0003-1564-8996
Funding Agency and Grant Number
Corresponding Author	Yusuf Ziya Şener, MD, Department of Cardiology, Thoraxcentrum, Erasmus MC, Beypazarı, Rotterdam 3015 GD, Netherlands. yzsener@yahoo.com.tr
Key Words	Immunoglobulin A nephropathy; Telitacicept; Complement inhibitors; B-cell lineage depletion; Anti-proteinuric treatment
Core Tip	Immunoglobulin A nephropathy represents the most prevalent form of primary glomerulonephritis, with the potential for progression to end-stage renal disease. Lifestyle modifications, dietary alterations and anti-proteinuric pharmacological agents have been demonstrated to induce clinical remission in the majority of cases. However, some cases do not respond the supportive therapy. Short term of corticosteroids should be considered in unresponsive cases. However, novel therapeutic strategies are required for patients with steroid-refractory disease. B-cell lineage depletion therapies and complement system inhibitors represent promising avenues for future research and may be considered in cases of persistent disease despite guideline-directed medical treatment.
Publish Date	2025-03-19 06:12
Citation	<p>Şener YZ, Şener S. Treatment of immunoglobulin A nephropathy: A current perspective and future prospects. <i>World J Clin Cases</i> 2025; 13(19): 101196</p>
URL	https://www.wjgnet.com/2307-8960/full/v13/i19/101196.htm
DOI	https://dx.doi.org/10.12998/wjcc.v13.i19.101196

Full Article (PDF)	WJCC-13-101196-with-cover.pdf
Manuscript File	101196_Auto_Edited_025349.docx
Answering Reviewers	101196-answering-reviewers.pdf
Audio Core Tip	101196-audio.m4a
Conflict-of-Interest Disclosure Form	101196-conflict-of-interest-statement.pdf
Copyright License Agreement	101196-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	101196-non-native-speakers.pdf
Peer-review Report	101196-peer-reviews.pdf
Scientific Misconduct Check	101196-scientific-misconduct-check.png
Scientific Editor Work List	101196-scientific-editor-work-list.pdf
CrossCheck Report	101196-crosscheck-report.pdf